Modality
Small Molecule
MOA
C5i
Target
DLL3
Pathway
PD-1/PD-L1
TTR AmyloidosisProstate CaMeso
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Oct 2027
Phase 2Current
NCT05988314
748 pts·Meso
2023-07→2027-10·Not yet recruiting
NCT08557954
682 pts·Meso
2023-11→TBD·Completed
1,430 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-131.5y awayPh3 Readout· Meso
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Not yet…
P2/3
Complet…
Catalysts
Ph3 Readout
2027-10-13 · 1.5y away
Meso
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05988314 | Phase 2/3 | Meso | Not yet recr... | 748 | Safety |
| NCT08557954 | Phase 2/3 | Meso | Completed | 682 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 |